Kiromic BioPharma Inc (KRBP) Börsenkurse

Kiromic BioPharma Activates the University of Arizona Cancer Center as the Fifth Clinical Trial Site in the Ongoing Phase 1 Deltacel-01 Trial

Kiromic BioPharma, Inc. (OTCQB: KRBP) (“Kiromic” or the “Company”) announces that the University of Arizona Cancer Center (UACC) has been...

Kiromic BioPharma Advances Deltacel-01 Into Expansion Phase Following Safety Monitoring Committee’s Unanimous Recommendation

Kiromic BioPharma, Inc. (OTCQB: KRBP) (“Kiromic” or the “Company”) announced today that the Deltacel-01 Safety Monitoring Committee (SMC) has...

Form 4 - Statement of changes in beneficial ownership of securities

Kiromic BioPharma’s Deltacel Receives FDA Fast Track Designation

Kiromic BioPharma, Inc. (OTCQB: KRBP) (“Kiromic” or the “Company”) announces that the U.S. Food and Drug Administration (FDA) has granted Fast...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Kiromic BioPharma Provides Update on Part 1 of the Deltacel-01 Trial

On track to initiate Part 2 in September Kiromic BioPharma, Inc. (OTCQB: KRBP) (“Kiromic” or the “Company”) reports interim results near the...

Kiromic BioPharma Reports 20% Tumor Size Reduction at Eight Months in First Patient Enrolled in Deltacel-01

Kiromic BioPharma, Inc. (OTCQB: KRBP) (“Kiromic” or the “Company”), reports favorable eight-month follow-up results from the first patient...

Kiromic BioPharma to Advance Deltacel-01 Clinical Trial to Part 2, Expansion Phase

Enrollment in the Expansion Phase Expected to Commence in September Deltacel Safety Confirmed at Day 30 in Trial’s Fifth Patient; Efficacy...

Form 8-K - Current report

Form 8-K - Current report

Kiromic BioPharma Provides Updates on its Deltacel-01 Clinical Trial

Follow-up Findings Show Stable Disease FDA and IRB Approve IND for a Single-Use, Single-Patient Treatment with Deltacel Fast Track Designation...

Form 4 - Statement of changes in beneficial ownership of securities